染色质靶向药物在癌症和免疫中的作用
Chromatin targeting drugs in cancer and immunity.
机构信息
Epinova DPU, Immuno-Inflammation Therapy Area, Medicines Research Centre, GlaxoSmithKline, Stevenage SG1 2NY, United Kingdom.
出版信息
Genes Dev. 2013 Aug 15;27(16):1731-8. doi: 10.1101/gad.221895.113.
Abstract
Recent advances in the enzymology of transcription and chromatin regulation have led to the discovery of proteins that play a prominent role in cell differentiation and the maintenance of specialized cell functions. Knowledge about post-synthetic DNA and histone modifications as well as information about the rules that guide the formation of multimolecular chromatin-bound complexes have helped to delineate gene-regulating pathways and describe how these pathways are altered in various pathological conditions. The present review focuses on the emerging area of therapeutic interference with chromatin function for the purpose of cancer treatment and immunomodulation.
摘要
近年来，转录和染色质调控的酶学研究取得了进展，发现了在细胞分化和维持特定细胞功能中起重要作用的蛋白质。人们对转录后 DNA 和组蛋白修饰的认识，以及关于指导多分子染色质结合复合物形成的规则的信息，有助于阐明基因调控途径，并描述这些途径在各种病理条件下是如何改变的。本综述重点介绍了针对癌症治疗和免疫调节目的的染色质功能治疗干预这一新兴领域。
相似文献
1
Chromatin targeting drugs in cancer and immunity.染色质靶向药物在癌症和免疫中的作用
Genes Dev. 2013 Aug 15;27(16):1731-8. doi: 10.1101/gad.221895.113.
2
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.癌症中的染色质药物治疗：最新进展与新方法
Mol Cell. 2015 Nov 19;60(4):561-70. doi: 10.1016/j.molcel.2015.10.042.
3
Chromatin remodeling, cancer and chemotherapy.染色质重塑、癌症与化疗
Curr Med Chem. 2006;13(24):2909-19. doi: 10.2174/092986706778521850.
4
PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.PRC2与SWI/SNF染色质重塑复合体在健康与疾病中的作用
Biochemistry. 2016 Mar 22;55(11):1600-14. doi: 10.1021/acs.biochem.5b01191. Epub 2016 Feb 17.
5
Histone profiles in cancer.癌症中的组蛋白谱。
Pharmacol Ther. 2015 Oct;154:87-109. doi: 10.1016/j.pharmthera.2015.07.004. Epub 2015 Jul 22.
6
A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.多梳抑制复合物的非典型功能促进人巨细胞病毒裂解型 DNA 复制，并作为抗病毒干预的新型细胞靶标。
J Virol. 2019 Apr 17;93(9). doi: 10.1128/JVI.02143-18. Print 2019 May 1.
7
Targeting Polycomb systems to regulate gene expression: modifications to a complex story.靶向多梳系统以调控基因表达：复杂故事的修正
Nat Rev Mol Cell Biol. 2015 Nov;16(11):643-649. doi: 10.1038/nrm4067. Epub 2015 Sep 30.
8
Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2.EZH2对癌症生物学和抗肿瘤免疫的表观遗传调控
Oncotarget. 2016 Dec 20;7(51):85624-85640. doi: 10.18632/oncotarget.12928.
9
Epigenetics in cancer: targeting chromatin modifications.癌症中的表观遗传学：靶向染色质修饰
Mol Cancer Ther. 2009 Jun;8(6):1409-20. doi: 10.1158/1535-7163.MCT-08-0860. Epub 2009 Jun 9.
10
Histone deacetylases as targets for treatment of multiple diseases.组蛋白去乙酰化酶作为治疗多种疾病的靶点。
Clin Sci (Lond). 2013 Jun;124(11):651-62. doi: 10.1042/CS20120504.
引用本文的文献
1
Targeting lysine acetylation readers and writers.靶向赖氨酸乙酰化的识别蛋白和写入蛋白。
Nat Rev Drug Discov. 2025 Feb;24(2):112-133. doi: 10.1038/s41573-024-01080-6. Epub 2024 Nov 21.
2
Bromodomain inhibitors and therapeutic applications.溴结构域抑制剂及其治疗应用。
Curr Opin Chem Biol. 2023 Aug;75:102323. doi: 10.1016/j.cbpa.2023.102323. Epub 2023 May 17.
3
Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models.评估小分子 BRD4 降解剂 CFT-2718 在小细胞肺癌和胰腺癌模型中的作用。
Mol Cancer Ther. 2021 Aug;20(8):1367-1377. doi: 10.1158/1535-7163.MCT-20-0831. Epub 2021 May 27.
4
Structure-Based Screening of Tetrazolylhydrazide Inhibitors versus KDM4 Histone Demethylases.基于结构的四唑酰肼类抑制剂对KDM4组蛋白去甲基化酶的筛选
ChemMedChem. 2019 Nov 6;14(21):1828-1839. doi: 10.1002/cmdc.201900441. Epub 2019 Oct 10.
5
Emerging roles of and therapeutic strategies targeting BRD4 in cancer.BRD4 在癌症中的新兴作用和治疗靶点。
Cell Immunol. 2019 Mar;337:48-53. doi: 10.1016/j.cellimm.2019.02.001. Epub 2019 Feb 4.
6
Maintenance of macrophage transcriptional programs and intestinal homeostasis by epigenetic reader SP140.表观遗传阅读器SP140维持巨噬细胞转录程序和肠道稳态
Sci Immunol. 2017 Mar 3;2(9). doi: 10.1126/sciimmunol.aag3160.
7
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.组蛋白去乙酰化酶与溴结构域联合抑制在非小细胞肺癌中的协同免疫刺激作用及治疗益处
Cancer Discov. 2017 Aug;7(8):852-867. doi: 10.1158/2159-8290.CD-16-1020. Epub 2017 Apr 13.
8
Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches.靶向自然杀伤细胞的抗癌免疫疗法：临床与临床前方法
Front Immunol. 2016 Apr 21;7:152. doi: 10.3389/fimmu.2016.00152. eCollection 2016.
9
EZH2 as a mediator of treatment resistance in melanoma.EZH2作为黑色素瘤治疗耐药的介导因子。
Pigment Cell Melanoma Res. 2016 Sep;29(5):500-7. doi: 10.1111/pcmr.12481. Epub 2016 May 25.
10
Transcriptional Activation of Inflammatory Genes: Mechanistic Insight into Selectivity and Diversity.炎症基因的转录激活：对选择性和多样性的机制洞察
Biomolecules. 2015 Nov 11;5(4):3087-111. doi: 10.3390/biom5043087.
本文引用的文献
1
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.组蛋白 H3.3K27M 突变在小儿神经胶质瘤中重塑 H3K27 甲基化和基因表达。
Genes Dev. 2013 May 1;27(9):985-90. doi: 10.1101/gad.217778.113. Epub 2013 Apr 19.
2
Selective inhibition of tumor oncogenes by disruption of super-enhancers.通过破坏超级增强子选择性抑制肿瘤癌基因。
Cell. 2013 Apr 11;153(2):320-34. doi: 10.1016/j.cell.2013.03.036.
3
Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.功能获得性 H3 突变抑制 PRC2 活性，该突变存在于小儿脑胶质瘤中。
Science. 2013 May 17;340(6134):857-61. doi: 10.1126/science.1232245. Epub 2013 Mar 28.
4
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.通过 BET 溴结构域抑制靶向神经母细胞瘤中的 MYCN。
Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.
5
BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses.BET 蛋白功能对于炎症反应是必需的：Brd2 基因敲除和 BET 抑制剂 JQ1 损害了小鼠巨噬细胞的炎症反应。
J Immunol. 2013 Apr 1;190(7):3670-8. doi: 10.4049/jimmunol.1202838. Epub 2013 Feb 18.
6
P-TEFb as a target to reactivate latent HIV: two Brds are now in hand.以 P-TEFb 为靶点重新激活潜伏的 HIV：现在有两种药物可供选择。
Cell Cycle. 2013 Feb 1;12(3):392-3. doi: 10.4161/cc.23556. Epub 2013 Jan 16.
7
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.在去势抵抗性前列腺癌细胞中，EZH2 致癌活性是独立于 Polycomb 的。
Science. 2012 Dec 14;338(6113):1465-9. doi: 10.1126/science.1227604.
8
Epigenetics and bacterial infections.表观遗传学与细菌感染。
Cold Spring Harb Perspect Med. 2012 Dec 1;2(12):a010272. doi: 10.1101/cshperspect.a010272.
9
Epigenetic therapy leaps ahead with specific targeting of EZH2.表观遗传学治疗通过特异性靶向 EZH2 取得突破。
Cancer Cell. 2012 Nov 13;22(5):569-70. doi: 10.1016/j.ccr.2012.10.016.
10
EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex.EZH2 产生一个被 DCAF1/DDB1/CUL4 E3 泛素连接酶复合物识别的甲基化降解结构域。
Mol Cell. 2012 Nov 30;48(4):572-86. doi: 10.1016/j.molcel.2012.09.004. Epub 2012 Oct 11.
Zotero 插件